References
- Abbate A, Toldo S, Marchetti C et al (2020) Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ Res 126:1260–1280.
https://doi.org/10.1161/CIRCRESAHA.120.315937 - Abuduhalike R, Sun J, Mahemuti A (2020) Correlation study of the long-term prognosis of venous thromboembolism and inflammatory gene polymorphisms. Int J Gen Med 13:1559–1566.
https://doi.org/10.2147/IJGM.S286809 - Abu-Fanne R, Stepanova V, Litvinov RI et al (2019) Neutrophil alpha-defensins promote thrombosis in vivo by altering fibrin formation, structure, and stability. Blood 133:481–493.
https://doi.org/10.1182/blood-2018-07-861237 - Abul Y, Karakurt S, Ozben B et al (2011) C-reactive protein in acute pulmonary embolism. J Investig Med 59:8–14.
https://doi.org/10.2310/jim.0b013e31820017f2 - Acanfora D, Gheorghiade M, Trojano L et al (2001) Relative lymphocyte count: A prognostic indicator of mortality in elderly patients with congestive heart failure. Am Heart J 142:167–173.
https://doi.org/10.1067/mhj.2001.115792 - Afzal A, Noor HA, Gill SA et al (1999) Leukocytosis in acute pulmonary embolism. Chest 115:1329–1332.
https://doi.org/10.1378/chest.115.5.1329 - Akgullu C, Omurlu IK, Eryilmaz U et al (2015) Predictors of early death in patients with acute pulmonary embolism. Am J Emerg Med 33:214–221.
https://doi.org/10.1016/j.ajem.2014.11.022 - Alqudah M, Qandeel H, Al-Zoubi N et al (2017) Changes of serum growth factors profiles in patients with venous thromboembolism. Scand J Clin Lab Invest 77:595–600.
https://doi.org/10.1080/00365513.2017.1379607 - Annes JP, Munger JS, Rifkin DB (2003) Making sense of latent TGFbeta activation. J Cell Sci 116(Pt 2):217–224.
https://doi.org/10.1242/jcs.00229 - Apostolakis S, Vogiatzi K, Amanatidou V et al (2009) Interleukin 8 and cardiovascular disease. Cardiovasc Res 84:353–360.
https://doi.org/10.1093/cvr/cvp241 - Ates H, Ates I, Kundi H et al (2017) Diagnostic validity of hematologic parameters in evaluation of massive pulmonary embolism. J Clin Lab Anal 31:e22072.
https://doi.org/10.1002/jcla.22072 - Baldini C, Moriconi FR, Galimberti S et al (2021) The JAK-STAT pathway: An emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. Eur Heart J 42:4389–4400.
https://doi.org/10.1093/eurheartj/ehab447 - Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9:361–371.
https://doi.org/10.1038/nrc2628 - Balta S, Demirkol S, Unlu M et al (2013) Mean platelet volume in patients with ischemic stroke. Eur Rev Med Pharmacol Sci 17:3121–3122.
- Beckers MM, Ruven HJ, Haas FJ et al (2010) Single nucleotide polymorphisms in inflammation-related genes are associated with venous thromboembolism. Eur J Intern Med 21:289–292.
https://doi.org/10.1016/j.ejim.2010.04.001 - Bermudez B, Lopez S, Pacheco YM et al (2008) Influence of postprandial triglyceride-rich lipoproteins on lipid-mediated gene expression in smooth muscle cells of the human coronary artery. Cardiovasc Res 79:294–303.
https://doi.org/10.1093/cvr/cvn082 - Bi W, Liang S, He Z et al (2021) The prognostic value of the serum levels of brain natriuretic peptide, troponin I, and D-dimer, in addition to the neutrophil-to-lymphocyte ratio, for the disease evaluation of patients with acute pulmonary embolism. Int J Gen Med 14:303–308.
https://doi.org/10.2147/IJGM.S288975 - Bittar LF, Silva LQD, Orsi FLA et al (2020) Increased inflammation and endothelial markers in patients with late severe post-thrombotic syndrome. PLoS One 15:e0227150.
https://doi.org/10.1371/journal.pone.0227150 - Blann AD, Tan KT, Tayebjee MH et al (2005) Soluble CD40L in peripheral artery disease. Relationship with disease severity, platelet markers and the effects of angioplasty. Thromb Haemost 93:578–583.
https://doi.org/10.1160/TH04-09-0586 - Bonaventura A, Vecchie A, Dagna L et al (2021) Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol 21:319–329.
https://doi.org/10.1038/s41577-021-00536-9 - Bontekoe E, Brailovsky Y, Hoppensteadt D et al (2021) Upregulation of inflammatory cytokines in pulmonary embolism using biochip-array profiling. Clin Appl Thromb Hemost 27:10760296211013107.
https://doi.org/10.1177/10760296211013107 - Bootcov MR, Bauskin AR, Valenzuela SM et al (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-Beta superfamily. Proc Natl Acad Sci USA 94:11514–11519.
https://doi.org/10.1073/pnas.94.21.11514 - Bovill EG, Bild DE, Heiss G et al (1996) White blood cell counts in persons aged 65 years or more from the Cardiovascular Health Study. Correlations with baseline clinical and demographic characteristics. Am J Epidemiol 143:1107–1115.
https://doi.org/10.1093/oxfordjournals.aje.a008687 - Brehm MA (2017) Von Willebrand factor processing. Hamostaseologie 37:59–72.
https://doi.org/10.5482/HAMO-16-06-0018 - Bucek RA, Reiter M, Quehenberger P et al (2002) C-reactive protein in the diagnosis of deep vein thrombosis. Br J Haematol 119:385–389.
https://doi.org/10.1046/j.1365-2141.2002.03886.x - Buyuksirin M, Anar C, Polat G et al (2021) Can the level of CRP in acute pulmonary embolism determine early mortality? Turk Thorac J 22:4–10.
https://doi.org/10.5152/TurkThoracJ.2020.19048 - Campbell CM, Kahwash R (2020) Will complement inhibition be the new target in treating COVID-19-related systemic thrombosis? Circulation 141:1739–1741.
https://doi.org/10.1161/CIRCULATIONAHA.120.047419 - Celik A, Ozcan IT, Gündes A et al (2015) Usefulness of admission hematologic parameters as diagnostic tools in acute pulmonary embolism. Kaohsiung J Med Sci 31:145–149.
https://doi.org/10.1016/j.kjms.2014.12.004 - Cha SI, Shin KM, Lee J et al (2012) Clinical relevance of pulmonary infarction in patients with pulmonary embolism. Thromb Res 130:e1–e5.
https://doi.org/10.1016/j.thromres.2012.03.012 - Charkes ND, Dugan MA, Maier WP et al (1974) Scintigraphic detection of deep-vein thrombosis with 131I-fibrinogen. J Nucl Med 15:1163–1166.
- Chung T, Connor D, Joseph J et al (2007) Platelet activation in acute pulmonary embolism. J Thromb Haemost 5:918–924.
https://doi.org/10.1111/j.1538-7836.2007.02461.x - Clyne B, Olshaker JS (1999) The C-reactive protein. J Emerg Med 17:1019–1025.
https://doi.org/10.1016/s0736-4679(99)00135-3 - Coll RC, Hill JR, Day CJ et al (2019) MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat Chem Biol 15:556–559.
https://doi.org/10.1038/s41589-019-0277-7 - Damas JK, Otterdal K, Yndestad A et al (2004) Soluble CD40 ligand in pulmonary arterial hypertension: Possible pathogenic role of the interaction between platelets and endothelial cells. Circulation 110:999–1005.
https://doi.org/10.1161/01.CIR.0000139859.68513.FC - Darbousset R, Thomas GM, Mezouar S et al (2012) Tissue factor-positive neutrophils bind to injured endothelial wall and initiate thrombus formation. Blood 120:2133–2143.
https://doi.org/10.1182/blood-2012-06-437772 - Darwish I, Fareed J, Brailovsky Y et al (2022) Dysregulation of biomarkers of hemostatic activation and inflammatory processes are associated with adverse outcomes in pulmonary embolism. Clin Appl Thromb Hemost 28:10760296211064898.
https://doi.org/10.1177/10760296211064898 - Demelo-Rodriguez P, Galeano-Valle F, Marcelo-Ayala A et al (2020) C-reactive protein level predicts 30-day mortality and bleeding in patients with venous thromboembolism: A prospective single-center study. Med Clin 155:51–56.
https://doi.org/10.1016/j.medcli.2019.09.024 - Dewachter L, Dewachter C (2018) Inflammation in right ventricular failure: Does it matter? Front Physiol 9:1056.
https://doi.org/10.3389/fphys.2018.01056 - Di Nisio M, van Es N, Buller HR (2016) Deep vein thrombosis and pulmonary embolism. Lancet 388:3060–3073.
https://doi.org/10.1016/S0140-6736(16)30514-1 - Ding J, Yue X, Tian X et al (2023) Association between inflammatory biomarkers and venous thromboembolism: A systematic review and meta-analysis. Thromb J 21:82.
https://doi.org/10.1186/s12959-023-00526-y - Dirican N, Duman A, Sađlam G et al (2016) The diagnostic significance of signal peptide-complement C1r/C1s, Uegf, and Bmp1-epidermal growth factor domain-containing protein-1 levels in pulmonary embolism. Ann Thorac Med 11:277–282.
https://doi.org/10.4103/1817-1737.191876 - Du T, Tan Z (2014) Relationship between deep venous thrombosis and inflammatory cytokines in postoperative patients with malignant abdominal tumors. Braz J Med Biol Res 47:1003–1007.
https://doi.org/10.1590/1414-431X20143695 - Dunne A, O'Neill LA (2003) The interleukin-1 receptor/Toll-like receptor superfamily: Signal transduction during inflammation and host defense. Sci STKE 2003:re3.
https://doi.org/10.1126/stke.2003.171.re3 - Duran L, Kayhan S, Guzel A et al (2014) The prognostic values of GDF-15 in comparison with NT-proBNP in patients with normotensive acute pulmonary embolism. Clin Lab 60:1365–1371.
https://doi.org/10.7754/clin.lab.2013.130827 - Duygu H, Barisik V, Kurt H et al (2008) Prognostic value of plasma soluble CD40 ligand in patients with chronic non-valvular atrial fibrillation. Europace 10:210–214.
https://doi.org/10.1093/europace/eum284 - Dzikowska-Diduch O, Domienik-Karlowicz J, Gorska E et al (2017) E-selectin and sICAM-1, biomarkers of endothelial function, predict recurrence of venous thromboembolism. Thromb Res 157:173–180.
https://doi.org/10.1016/j.thromres.2017.07.027 - Eggers AS, Hafian A, Lerchbaumer MH et al (2023) Acute infections and inflammatory biomarkers in patients with acute pulmonary embolism. J Clin Med 12:546.
https://doi.org/10.3390/jcm12103546 - Engelmann B, Massberg S (2013) Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 13:34–45.
https://doi.org/10.1038/nri3345 - Engström G, Melander O, Hedblad B (2009) Leukocyte count and incidence of hospitalizations due to heart failure. Circ Heart Fail 2:217–222.
https://doi.org/10.1161/CIRCHEARTFAILURE.108.827071 - Falk E, Shah PK, Fuster V (1995) Coronary plaque disruption. Circulation 92:657–671.
https://doi.org/10.1161/01.cir.92.3.657 - Farah R, Nseir W, Kagansky D et al (2020) The role of neutrophil-lymphocyte ratio, and mean platelet volume in detecting patients with acute venous thromboembolism. J Clin Lab Anal 34:e23010.
https://doi.org/10.1002/jcla.23010 - Furman MI, Gore JM, Anderson FA et al (2004) Elevated leukocyte count and adverse hospital events in patients with acute coronary syndromes: Findings from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 147:42–48.
https://doi.org/10.1016/j.ahj.2003.07.003 - Galeano-Valle F, Ordieres-Ortega L, Oblitas CM et al (2021) Inflammatory biomarkers in the short-term prognosis of venous thromboembolism: A narrative review. Int J Mol Sci 22:2627.
https://doi.org/10.3390/ijms22052627 - Galliazzo S, Nigro O, Bertu L et al (2018) Prognostic role of neutrophils to lymphocytes ratio in patients with acute pulmonary embolism: A systematic review and meta-analysis of the literature. Intern Emerg Med 13:603–608.
https://doi.org/10.1007/s11739-018-1805-2 - Garlichs CD, Eskafi S, Raaz D et al (2001) Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 86:649–655.
https://doi.org/10.1136/heart.86.6.649 - Grimm RH Jr, Neaton JD, Ludwig W (1985) Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. JAMA 254:1932–1937.
- Grimnes G, Isaksen T, Tichelaar Y et al (2018) C-reactive protein and risk of venous thromboembolism: Results from a population-based case-crossover study. Haematologica 103:1245–1250.
https://doi.org/10.3324/haematol.2017.186957 - Heit JA (2015) Epidemiology of venous thromboembolism. Nat Rev Cardiol 12:464–474.
https://doi.org/10.1038/nrcardio.2015.83 - Henn V, Slupsky JR, Grafe M et al (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391:591–594.
https://doi.org/10.1038/35393 - Hogg K, Hinchliffe E, Haslam S et al (2013) Predicting short term mortality after investigation for venous thromboembolism. Thromb Res 131:e141–e146.
https://doi.org/10.1016/j.thromres.2013.01.030 - Horvei LD, Grimnes G, Hindberg K et al (2016) C-reactive protein, obesity, and the risk of arterial and venous thrombosis. J Thromb Haemost 14:1561–1571.
https://doi.org/10.1111/jth.13369 - Huang CM, Lin YC, Lin YJ et al (2011) Risk stratification and clinical outcomes in patients with acute pulmonary embolism. Clin Biochem 44:1110–1115.
https://doi.org/10.1016/j.clinbiochem.2011.06.077 - Huang SL, Xin HY, Wang XY et al (2023) Recent advances on the molecular mechanism and clinical trials of venous thromboembolism. J Inflamm Res 16:6167–6178.
https://doi.org/10.2147/JIR.S439205 - Humphries F, Shmuel-Galia L, Ketelut-Carneiro N et al (2020) Succination inactivates gasdermin D and blocks pyroptosis. Science 369:1633–1637.
https://doi.org/10.1126/science.abb9818 - Imiela AM, Mikolajczyk TP, Guzik TJ et al (2024) Acute pulmonary embolism and immunity in animal models. Arch Immunol Ther Exp 72:3.
https://doi.org/10.2478/aite-2024-0003 - Iwadate K, Doi M, Tanno K et al (2003) Right ventricular damage due to pulmonary embolism: Examination of the number of infiltrating macrophages. Forensic Sci Int 134:147–153.
https://doi.org/10.1016/s0379-0738(03)00138-5 - Jackson SP, Darbousset R, Schoenwaelder SM (2019) Thromboinflammation: Challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood 133:906–918.
https://doi.org/10.1182/blood-2018-11-882993 - Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T et al (2018) D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis. Br J Cancer 119:915–921.
https://doi.org/10.1038/s41416-018-0269-5 - Jayarangaiah A, Kariyanna PT, Chen X et al (2020) COVID-19-associated coagulopathy: An exacerbated immunothrombosis response. Clin Appl Thromb Hemost 26:1076029620943293.
https://doi.org/10.1177/1076029620943293 - Kahlenberg JM, Carmona-Rivera C, Smith CK et al (2013) Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J Immunol 190:1217–1226.
https://doi.org/10.4049/jimmunol.1202388 - Kahn SR, Comerota AJ, Cushman M et al (2014) The postthrombotic syndrome: Evidence-based prevention, diagnosis, and treatment strategies: A scientific statement from the American Heart Association. Circulation 130:1636–1661.
https://doi.org/10.1161/CIR.0000000000000130 - Kaptein FHJ, Kroft LJM, Hammerschlag G et al (2021) Pulmonary infarction in acute pulmonary embolism. Thromb Res 202:162–169.
https://doi.org/10.1016/j.thromres.2021.03.022 - Karabinos I, Koulouris S, Kranidis A et al (2009) Neutrophil count on admission predicts major in-hospital events in patients with a non-ST-segment elevation acute coronary syndrome. Clin Cardiol 32:561–568.
https://doi.org/10.1002/clc.20624 - Karatas MB, Ipek G, Onuk T et al (2016) Assessment of prognostic value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with pulmonary embolism. Acta Cardiol Sin 32:313–320.
https://doi.org/10.6515/acs20151013a - Kaya Z, Ozdemir K, Kayrak M et al (2012) Soluble CD40 ligand levels in acute pulmonary embolism: A prospective, randomized, controlled study. Heart Vessels 27:295–299.
https://doi.org/10.1007/s00380-011-0142-4 - Kayrak M, Erdogan HI, Solak Y et al (2014) Prognostic value of neutrophil to lymphocyte ratio in patients with acute pulmonary embolism: A retrospective study. Heart Lung Circ 23:56–62.
https://doi.org/10.1016/j.hlc.2013.06.004 - Kempf T, Zarbock A, Widera C et al (2011) GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 17:581–588.
https://doi.org/10.1038/nm.2354 - Kerr R, Stirling D, Ludlam CA (2001) Interleukin 6 and haemostasis. Br J Haematol 115:3–12.
https://doi.org/10.1046/j.1365-2141.2001.03061.x - Kimball AS, Obi AT, Diaz JA et al (2016) The emerging role of NETs in Venous thrombosis and immunothrombosis. Front Immunol 7:236.
https://doi.org/10.3389/fimmu.2016.00236 - Kline JA, Zeitouni R, Marchick MR et al (2008) Comparison of 8 biomarkers for prediction of right ventricular hypokinesis 6 months after submassive pulmonary embolism. Am Heart J 156:308–314.
https://doi.org/10.1016/j.ahj.2008.03.026 - Kluck V, Jansen T, Janssen M et al (2020) Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: An open-label, dose-adaptive, proof-of-concept, phase 2a trial. Lancet Rheumatol 2:e270–e280.
https://doi.org/10.1016/s2665-9913(20)30065-5 - Kolb-Bachofen V (1991) A review on the biological properties of C-reactive protein. Immunobiology 183:133–145.
https://doi.org/10.1016/S0171-2985(11)80193-2 - Konstantinides SV, Meyer G, Becattini C et al (2019) 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J 54:1901647.
https://doi.org/10.1183/13993003.01647-2019 - Konstantinides SV, Meyer G, Becattini C et al. (2020) 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41:543–603.
https://doi.org/10.1093/eurheartj/ehz405 - Kunutsor SK, Seidu S, Blom AW et al (2017) Serum C-reactive protein increases the risk of venous thromboembolism: A prospective study and meta-analysis of published prospective evidence. Eur J Epidemiol 32:657–667.
https://doi.org/10.1007/s10654-017-0277-4 - Kurtipek E, Buyukterzi Z, Buyukterzi M et al (2017) Endothelial dysfunction in patients with pulmonary thromboembolism: Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio. Clin Respir J 11:78–82.
https://doi.org/10.1111/crj.12308 - Lankeit M, Kempf T, Dellas C et al (2008) Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med 177:1018–1025.
https://doi.org/10.1164/rccm.200712-1786OC - Lewis HD, Liddle J, Coote JE et al (2015) Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat Chem Biol 11:189–191.
https://doi.org/10.1038/nchembio.1735 - Li P, Zhao W, Kaatz S et al (2021) Factors associated with risk of postdischarge thrombosis in patients with COVID-19. JAMA Netw Open 4:e2135397.
https://doi.org/10.1001/jamanetworkopen.2021.35397 - Liang W, Wei F, Yang C et al (2020) GDF-15 is associated with thrombus burden in patients with deep venous thrombosis. Thromb Res 187:148–153.
https://doi.org/10.1016/j.thromres.2020.01.022 - Lippi G, Salvagno GL, Danese E et al (2017) Serum concentration of growth differentiation factor-15 is independently associated with global platelet function and higher fibrinogen values in adult healthy subjects. Semin Thromb Hemost 43:621–628.
https://doi.org/10.1055/s-0037-1603358 - Luster AD (1998) Chemokines – chemotactic cytokines that mediate inflammation. N Engl J Med 338:436–445.
https://doi.org/10.1056/NEJM199802123380706 - Ma Y, Mao Y, He X et al (2016) The values of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in predicting 30 day mortality in patients with acute pulmonary embolism. BMC Cardiovasc Disord 16:123.
https://doi.org/10.1186/s12872-016-0304-5 - Machowski M, Ou-Pokrzewinska A, Perzanowska-Brzeszkiewicz K et al (2024) Predicting acute cardiovascular complications in COVID-19: Insights from a specialized cardiac referral department. Med Sci Monit 30:e942612.
https://doi.org/10.12659/MSM.942612 - Mackman N, Bergmeier W, Stouffer GA et al (2020) Therapeutic strategies for thrombosis: New targets and approaches. Nat Rev Drug Discov 19:333–352.
https://doi.org/10.1038/s41573-020-0061-0 - Marchena Yglesias PJ, Nieto Rodríguez JA, Serrano Martínez S et al (2006) [Acute-phase reactants and markers of inflammation in venous thromboembolic disease: Correlation with clinical and evolution parameters]. An Med Interna 23:105–110.
https://doi.org/10.4321/s0212-71992006000300002 - Marcos-Jubilar M, Lecumberri R, Paramo JA (2023) Immunothrombosis: Molecular aspects and new therapeutic perspectives. J Clin Med 12:1399.
https://doi.org/10.3390/jcm12041399 - Matos MF, Lourenco DM, Orikaza CM et al. (2011) The role of IL-6, IL-8 and MCP-1 and their promoter polymorphisms IL-6 -174GC, IL-8 -251AT and MCP-1 -2518AG in the risk of venous thromboembolism: A case-control study. Thromb Res 128:216–220.
https://doi.org/10.1016/j.thromres.2011.04.016 - Mazetto BM, Orsi FL, Barnabe A et al (2012) Increased ADAMTS13 activity in patients with venous thromboembolism. Thromb Res 130:889–893.
https://doi.org/10.1016/j.thromres.2012.09.009 - McDonald B, Davis RP, Kim SJ et al (2017) Platelets and neutrophil extracellular traps collaborate to promote intravascular coagulation during sepsis in mice. Blood 129:1357–1367.
https://doi.org/10.1182/blood-2016-09-741298 - Memon AA, Sundquist K, Wang X et al (2014) Transforming growth factor (TGF)-beta levels and unprovoked recurrent venous thromboembolism. J Thromb Thrombolysis 38:348–354.
https://doi.org/10.1007/s11239-013-1047-0 - Mitchell AM, Nordenholz KE, Kline JA (2008) Tandem measurement of D-dimer and myeloperoxidase or C-reactive protein to effectively screen for pulmonary embolism in the emergency department. Acad Emerg Med 15:800–805.
https://doi.org/10.1111/j.1553-2712.2008.00204.x - Mosquera MS, Diaz JA (2023) Back to basics: Theory of thrombus formation and potential implications for therapies? Tech Vasc Interv Radiol 26:100894.
https://doi.org/10.1016/j.tvir.2023.100894 - Munzer P, Negro R, Fukui S et al (2021) NLRP3 inflammasome assembly in neutrophils is supported by PAD4 and promotes NETosis under sterile conditions. Front Immunol 12:683803.
https://doi.org/10.3389/fimmu.2021.683803 - Murthy P, Durco F, Miller-Ocuin JL et al (2017) The NLRP3 inflammasome and bruton's tyrosine kinase in platelets co-regulate platelet activation, aggregation, and in vitro thrombus formation. Biochem Biophys Res Commun 483:230–236.
https://doi.org/10.1016/j.bbrc.2016.12.161 - Najarro M, Rodriguez C, Morillo R et al (2024) C-reactive protein and risk of right ventricular dysfunction and mortality in patients with acute symptomatic pulmonary embolism. Arch Bronconeumol 60:344–349.
https://doi.org/10.1016/j.arbres.2024.03.024 - Najem MY, Couturaud F, Lemarie CA (2020) Cytokine and chemokine regulation of venous thromboembolism. J Thromb Haemost 18:1009–1019.
https://doi.org/10.1111/jth.14759 - Natorska J, Ząbczyk M, Undas A (2023) Neutrophil extracellular traps (NETs) in cardiovascular diseases: From molecular mechanisms to therapeutic interventions. Kardiol Pol 81:1205–1216.
https://doi.org/10.33963/v.kp.98520 - Nidorf SM, Fiolet ATL, Mosterd A et al (2020) Colchicine in patients with chronic coronary disease. N Engl J Med 383:1838–1847.
https://doi.org/10.1056/NEJMoa2021372 - Paralkar VM, Vail AL, Grasser WA et al (1998) Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family. J Biol Chem 273:13760–13767.
https://doi.org/10.1074/jbc.273.22.13760 - Peng R, Yin W, Wang F et al (2023) Neutrophil levels upon admission for the assessment of acute pulmonary embolism with intermediate- and high-risk: An indicator of thrombosis and inflammation. Thromb J 21:28.
https://doi.org/10.1186/s12959-023-00471-w - Phan T, Brailovsky Y, Fareed J et al (2020) Neutrophil-to-Lymphocyte and platelet-to-lymphocyte ratios predict all-cause mortality in acute pulmonary embolism. Clin Appl Thromb Hemost 26:1076029619900549.
https://doi.org/10.1177/1076029619900549 - Piazza G (2015) Beyond Virchow's Triad: Does cardiovascular inflammation explain the recurrent nature of venous thromboembolism? Vasc Med 20:102–104.
https://doi.org/10.1177/1358863X14568706 - Poisner A, Bass D, Fletcher A et al (2018) Evidence for angiotensin mediation of the late histopathological effects of pulmonary fat embolism: Protection by losartan in a rat model. Exp Lung Res 44:361–367.
https://doi.org/10.1177/1076029619900549 - Potere N, Abbate A, Kanthi Y et al (2023) Inflammasome signaling, thromboinflammation, and venous thromboembolism. JACC Basic Transl Sci 8:1245–1261.
https://doi.org/10.1016/j.jacbts.2023.03.017 - Rabinovich A, Cohen JM, Cushman M et al (2015) Association between inflammation biomarkers, anatomic extent of deep venous thrombosis, and venous symptoms after deep venous thrombosis. J Vasc Surg Venous Lymphat Disord 3:347–353. e1.
https://doi.org/10.1016/j.jvsv.2015.04.005 - Rider P, Carmi Y, Guttman O et al (2011) IL-1alpha and IL-1beta recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol 187:4835–4843.
https://doi.org/10.4049/jimmunol.1102048 - Ridker PM (2016) From C-reactive protein to interleukin-6 to interleukin-1: Moving upstream to identify novel targets for atheroprotection. Circ Res 118:145–156.
https://doi.org/10.1161/CIRCRESAHA.115.306656 - Ridker PM, Everett BM, Thuren T et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119–1131.
https://doi.org/10.1056/NEJMoa1707914 - Rosales C (2018) Neutrophil: A cell with many roles in inflammation or several cell types? Front Physiol 9:113.
https://doi.org/10.3389/fphys.2018.00113 - Rossaint J, Vestweber D, Zarbock A (2013) GDF-15 prevents platelet integrin activation and thrombus formation. J Thromb Haemost 11:335–344.
https://doi.org/10.1111/jth.12100 - Roumen-Klappe EM, Janssen MC, Van Rossum J et al (2009) Inflammation in deep vein thrombosis and the development of post-thrombotic syndrome: A prospective study. J Thromb Haemost 7:582–587.
https://doi.org/10.1111/j.1538-7836.2009.03286.x - Ryan TAJ, O'Neill LAJ (2022) Innate immune signaling and immunothrombosis: New insights and therapeutic opportunities. Eur J Immunol 52:1024–1034.
https://doi.org/10.1002/eji.202149410 - Ryan TAJ, Preston RJS, O'Neill LAJ (2022) Immunothrombosis and the molecular control of tissue factor by pyroptosis: Prospects for new anticoagulants. Biochem J 479:731–750.
https://doi.org/10.1002/eji.202149410 - Schulz C, Engelmann B, Massberg S (2013) Crossroads of coagulation and innate immunity: The case of deep vein thrombosis. J Thromb Haemost 11(Suppl 1):233–241.
https://doi.org/10.1111/jth.12261 - Sharma A, Stevens SR, Lucas J et al (2017) Utility of growth differentiation factor-15, a marker of oxidative stress and inflammation, in chronic heart failure: Insights from the HF-ACTION study. JACC Heart Fail 5:724–734.
https://doi.org/10.1016/j.jchf.2017.07.013 - Shen Q, Dong X, Tang X et al (2017) Risk factors and prognosis value of venous thromboembolism in patients with advanced non-small cell lung cancer: A case-control study. J Thorac Dis 9:5068–5074.
https://doi.org/10.21037/jtd.2017.11.116 - Skowronska M, Skrzynska M, Machowski M et al (2020) Plasma growth differentiation factor 15 levels for predicting serious adverse events and bleeding in acute pulmonary embolism: A prospective observational study. Pol Arch Intern Med 130:757–765.
https://doi.org/10.20452/pamw.15515 - Smilowitz NR, Kunichoff D, Garshick M et al (2021) C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J 42:2270–2279.
https://doi.org/10.1093/eurheartj/ehaa1103 - Soylu K, Gedikli O, Eksi A et al (2016) Neutrophil-to-lymphocyte ratio for the assessment of hospital mortality in patients with acute pulmonary embolism. Arch Med Sci 12:95–100.
https://doi.org/10.5114/aoms.2016.57585 - Staessens S, Denorme F, Francois O et al (2020) Structural analysis of ischemic stroke thrombi: Histological indications for therapy resistance. Haematologica 105:498–507.
https://doi.org/10.3324/haematol.2019.219881 - Stark K, Massberg S (2021) Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol 18:666–682.
https://doi.org/10.1038/s41569-021-00552-1 - Stewart LK, Nordenholz KE, Courtney M et al (2017) Comparison of acute and convalescent biomarkers of inflammation in patients with acute pulmonary embolism treated with systemic fibrinolysis vs. placebo. Blood Coagul Fibrinolysis 28:675–680.
https://doi.org/10.1097/MBC.0000000000000669 - Sun TW, Zhang JY, Li L et al (2011) Effect atorvastatin on serum tumor necrosis factor alpha and interleukin-1beta following acute pulmonary embolism. Exp Lung Res 37:78–81.
https://doi.org/10.3109/01902148.2010.514647 - Swanson KV, Deng M, Ting JP (2019) The NLRP3 inflammasome: Molecular activation and regulation to therapeutics. Nat Rev Immunol 19:477–489.
https://doi.org/10.1038/s41577-019-0165-0 - Tardif JC, Kouz S, Waters DD et al (2019) Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 381:2497–2505.
https://doi.org/10.1056/NEJMoa1912388 - Trujillo-Santos J, Di Micco P, Iannuzzo M et al (2008) Elevated white blood cell count and outcome in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 100:905–911.
- van Aken BE, den Heijer M, Bos GM et al (2000) Recurrent venous thrombosis and markers of inflammation. Thromb Haemost 83:536–539.
- Van Bruggen S, Martinod K (2023) The coming of age of neutrophil extracellular traps in thrombosis: Where are we now and where are we headed? Immunol Rev 314:376–398.
https://doi.org/10.1111/imr.13179 - Vijayan AL, Vanimaya, Ravindran S, Saikant R et al (2017) Procalcitonin: A promising diagnostic marker for sepsis and antibiotic therapy. J Intensive Care 5:51.
https://doi.org/10.1186/s40560-017-0246-8 - von Bruhl ML, Stark K, Steinhart A et al (2012) Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 209:819–835.
https://doi.org/10.1084/jem.20112322 - Vormittag R, Funk M, Mannhalter C et al (2006a) C-reactive protein 3′UTR +1444C>T polymorphism in patients with spontaneous venous thromboembolism. Atherosclerosis 188:406–411.
https://doi.org/10.1016/j.atherosclerosis.2005.11.006 - Vormittag R, Hsieh K, Kaider A et al (2006b) Interleukin-6 and interleukin-6 promoter polymorphism (-174) G > C in patients with spontaneous venous thromboembolism. Thromb Haemost 95:802–806.
- Wang X, Sundquist K, Svensson PJ et al (2019) Association of recurrent venous thromboembolism and circulating microRNAs. Clin Epigenetics 11:28.
https://doi.org/10.1186/s13148-019-0627-z - Wohlford GF, Van Tassell BW, Billingsley HE et al (2020) Phase 1B, randomized, double-blinded, dose escalation, single-center, repeat dose safety and pharmacodynamics study of the oral NLRP3 inhibitor dapansutrile in subjects with NYHA II-III systolic heart failure. J Cardiovasc Pharmacol 77:49–60.
https://doi.org/10.1097/FJC.0000000000000931 - Yang H, Wang H, Andersson U (2020) Targeting inflammation driven by HMGB1. Front Immunol 11:484.
https://doi.org/10.3389/fimmu.2020.00484 - Zabczyk M, Natorska J, Janion-Sadowska A et al (2020) Elevated lactate levels in acute pulmonary embolism are associated with prothrombotic fibrin clot properties: Contribution of NETs formation. J Clin Med 9:953.
https://doi.org/10.3390/jcm9040953 - Zacho J, Tybjaerg-Hansen A, Nordestgaard BG (2010) C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol 30:1672–1678.
https://doi.org/10.1161/ATVBAHA.109.198473 - Zagorski J, Debelak J, Gellar M et al (2003) Chemokines accumulate in the lungs of rats with severe pulmonary embolism induced by polystyrene microspheres. J Immunol 171:5529–5536.
https://doi.org/10.4049/jimmunol.171.10.5529 - Zagorski J, Gellar MA, Obraztsova M et al. (2007) Inhibition of CINC-1 decreases right ventricular damage caused by experimental pulmonary embolism in rats. J Immunol 179:7820–7826.
https://doi.org/10.4049/jimmunol.179.11.7820 - Zagorski J, Kline JA (2016) Differential effect of mild and severe pulmonary embolism on the rat lung transcriptome. Respir Res 17:86.
https://doi.org/10.1186/s12931-016-0405-9 - Zagorski J, Obraztsova M, Gellar MA (2009) Transcriptional changes in right ventricular tissues are enriched in the outflow tract compared with the apex during chronic pulmonary embolism in rats. Physiol Genomics 39:61–71.
https://doi.org/10.1152/physiolgenomics.00076.2009 - Zahorec R (2001) Ratio of neutrophil to lymphocyte counts – rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 102:5–14.
- Zarbock A, Polanowska-Grabowska RK, Ley K (2007) Platelet-neutrophil-interactions: Linking hemostasis and inflammation. Blood Rev 21:99–111.
https://doi.org/10.1016/j.blre.2006.06.001 - Zee RY, Glynn RJ, Cheng S et al (2009) An evaluation of candidate genes of inflammation and thrombosis in relation to the risk of venous thromboembolism: The Women's Genome Health Study. Circ Cardiovasc Genet 2:57–62.
https://doi.org/10.1161/CIRCGENETICS.108.801969 - Zhang Y, Zhang Z, Wei R et al (2020) IL (interleukin)-6 contributes to deep vein thrombosis and is negatively regulated by miR-338-5p. Arterioscler Thromb Vasc Biol 40:323–334.
https://doi.org/10.1161/ATVBAHA.119.313137